ORLANDO — In patients with classic congenital adrenal hyperplasia, crinecerfont conferred meaningful reductions in glucocorticoid dose and androstenedione level in children and improved ...

In the crinecerfont group, 74% achieved normal A4 levels versus 12% of placebo recipients. Previously reported results in kids showed a benefit for lowering glucocorticoid dose as well.

Crinecerfont isn’t a cure, but it’s a big step forward in CAH care. Doctors can now prescribe it as an add-on therapy to support glucocorticoid treatment. It may help lower your steroid dose.

Crinecerfont treatment also resulted in a statistically significant decrease in androstenedione levels at week 4 vs placebo (LS mean difference, -345ng/dL; P <.001).

Crinecerfont is an oral, selective corticotropin-releasing factor type 1 receptor antagonist that acts in the pituitary to decrease adrenal androgens production independently of glucocorticoids.

Crinecerfont is approved for people ages 4 and up with classic CAH. It’s designed to lower levels of androgens, which may reduce the need for high doses of glucocorticoids.

Crinecerfont Summary (Neurocrine Q1 2024 Corporate Presentation) CAH is a rare condition affecting between 1:10,000 to 1:15,000 people in the U.S. and Europe.

Neurocrine Biosciences has announced that the US Food and Drug Administration (FDA) has accepted its two New Drug Applications (NDA) for crinecerfont, granting them Priority Review designations ...

For pediatric patients, crinecerfont significantly reduced androstenedione (A4) by the end of the 4-week glucocorticoid stable period (-197 vs 71.0 ng/dL with placebo; least-squares mean ...

Neurocrine Biosciences has announced that the US Food and Drug Administration (FDA) has accepted its two New Drug Applications (NDA) for crinecerfont, granting them Priority Review designations.